Incidence and subtypes of dementia in three elderly populations of central Spain

Bermejo‐Pareja, Félix; Benito‐León, Julián; Vega, Saturio; Medrano, María; Román, Gustavo C.

doi:10.1016/j.jns.2007.07.021

Cited by 182 publications

(166 citation statements)

References 31 publications

Supporting

Mentioning

145

Contrasting

Unclassified

Order By: Relevance

“…Data for these analyses were derived from the Neurological Disorders in Central Spain (NEDICES) study, a longitudinal, population-based survey of the prevalence, incidence, and determinants of major ageassociated conditions of the elderly, including Parkinson's disease, essential tremor, stroke, and dementia [16][17][18][19][20][21][22][23][24][25]. Detailed accounts of the study population and sampling methods have been published [23][24][25].…”

Section: Study Populationmentioning

confidence: 99%

“…More specifically, the 37-MMSE was adopted to Chilean, Maltese, and Spanish socio-cultural backgrounds and then validated against clinical diagnoses of dementia [21,22,[30][31][32][33]. The 37-MMSE included all of the standard MMSE [30] items as well as three additional items: 1) an attention task, i.e., say 1, 3, 5, 7, 9 backwards; 2) a visual order, i.e., a man raising his arms; and 3) a simple construction task, i.e., copying two overlapping circles [21,22,[30][31][32][33].…”

Section: Neuropsychological Batterymentioning

confidence: 99%

See 1 more Smart Citation

Statins and Cognitive Functioning in the Elderly: A Population-Based Study

Benito-León

Louis

Vega³

et al. 2010

JAD

View full text Add to dashboard Cite

Abstract. In a 2009 Cochrane review, the authors concluded that there is good evidence that statins, given in late life to people at risk of vascular disease, have no effect in preventing Alzheimer's disease or dementia. A related issue, which remains unclear, is whether statins improve cognitive function. While some studies have shown a beneficial effect of statins on cognitive function, others have observed mild detrimental effects on cognition. Our aim was to assess cognitive function in community-dwelling elderly participants treated with statins compared with their untreated counterparts (i.e., controls) living in the same population. 137 population-dwelling participants who were receiving statins and 411 matched controls age 65 years (median = 72 years) in central Spain (the Neurological Disorders in Central Spain [NEDICES] study) underwent a neuropsychological assessment, including tests of global cognitive performance, frontal-executive function, verbal fluency, and memory. Median duration of statin treatment was 2 years. Of 137 participants receiving statins, 53 (38.7%) were taking pravastatin, 38 (27.7%) simvastatin, 37 (27.0%) lovastatin, 6 (4.4%) fluvastatin, and 3 (2.2%) atorvastatin. Although initial univariate analyses indicated some differences, after adjusting for age, gender, education, depressive symptoms, premorbid intelligence, medications that potentially affect cognitive function, and blood cholesterol levels, statin users and controls performed similarly on all neuropsychological tests. In this population-based sample, elderly participants treated with statins and untreated controls performed similarly in all tested cognitive areas. These results do not support a positive benefit of statins on cognition.

show abstract

Section: Study Populationmentioning

confidence: 99%

Section: Neuropsychological Batterymentioning

confidence: 99%

Statins and Cognitive Functioning in the Elderly: A Population-Based Study

Benito-León

Louis

Vega³

et al. 2010

JAD

View full text Add to dashboard Cite

show abstract

“…Tanto a incidência como a prevalência da demência aumentam quase exponencialmente com a idade, duplicando aproximadamente a cada 5 anos. [1][2][3][4][5][6][7][8][9] A incidência global de demência tem vindo a aumentar drasticamente nas últimas décadas. Se em 2005 se estimava cerca de 7,5/1000 pessoas por ano, ou seja, cerca de um novo caso a cada 7 segundos, 10 em 2012 as estimativas apontam para cerca de 7,7/1000 pessoas por ano, o que se traduz em cerca de 1 novo caso a cada 4 segundos.…”

Section: Introductionunclassified

Epidemiologia da Demência e da Doença de Alzheimer em Portugal: Estimativas da Prevalência e dos Encargos Financeiros com a Medicação

et al. 2015

View full text Add to dashboard Cite

Introduction:The incidence and prevalence of global dementia and Alzheimer's disease (AD) increase with age, almost doubling every five years after the sixth decade of life. Demographic aging is a reality in Portugal, being expectable that the number of dementia cases also increases. Even so, dementia-epidemiological data in Portugal is scarce and cost-of-illness studies are almost inexistent. Our aims were to obtain up-to-date information about the prevalence of dementia/ Alzheimer's disease in Portugal, to estimate the number of cases effectively diagnosed as Alzheimer's disease and to determine illness-costs with specific dementia treatment. Material and Methods:The numbers of age-adjusted prevalence of dementia obtained for Occidental Europe (Alzheimer's Disease International study), where applied to the resident population in Portugal (2013). Estimations related to diagnosis and treatment-costs were based in data provided by the Intercontinental Marketing Services Health (IMSH) -2013. Results:The estimated number of Portuguese people with dementia among those aged ≥ 60 years, is 160287, representing 5.91% of this population-stratum. Knowing Alzheimer's disease is responsible for 50-70% of all cases, we might conclude there are between 80144 and 112201 patients. According to IMSH-data, 76250 receive anti-dementia drugs and the costs of this kind of medication is 37 M€/year. Conclusions: As a consequence of the demographic aging, also the number of dementia cases increases. Aparentely, not all Alzheimer's disease patients receive the recommended medication, suggesting this condition is still under-diagnosed. However, figures indicate a positive progression with an increment of treated cases and a reduction of medication-costs.

show abstract

“…Когортные исследования свидетельствуют о 10-15 новых случаях на тысячу человеко-лет для всех типов деменции и 5-8 случаях болезни Альцгеймера (БА), что составляет приблизитель-но половину от общего числа ежегодных диа-гнозов [1,2]. Пожилой возраст является главным фактором риска заболевания: на каждые пять лет после 65-летия риск увеличивается примерно вдвое, вырастая от 3 случаев в 65 лет до 69 слу-чаев на тысячу человеко-лет к 95 годам [1,2].…”

unclassified

“…Пожилой возраст является главным фактором риска заболевания: на каждые пять лет после 65-летия риск увеличивается примерно вдвое, вырастая от 3 случаев в 65 лет до 69 слу-чаев на тысячу человеко-лет к 95 годам [1,2]. Со-гласно гипотезе «амилоидного каскада» в голов-ном мозге (в особенности в гиппокампе и коре мозга), ассоциированное со старением неравно-мерное распределение продуцирования и/или очистки бета-амилоидов (Aβ) приводит к посте-пенной аккумуляции и агрегации пептида, ини-циирующего нейродегенеративный каскад, кото-рый включает отложение амилоида, воспаление, повреждение и гибель нейронов [3].…”

unclassified